MARIPOSA Trial: AI Generated Global Network Visualization

Visualizing the Global MARIPOSA Discussion Network: How AI Maps KOL Interactions

The MARIPOSA Phase 3 trial has generated significant discussion among lung cancer specialists worldwide. Through social network analysis, we can visualize how key opinion leaders are sharing and discussing the landmark overall survival data presented at ELCC 2025.

Key nodes in the discussion network include:

• Dr. Noemi Reguart (@NReguart) shared the breakthrough finding that MARIPOSA showed significant OS improvement (HR 0.75) with amivantamab + lazertinib versus osimertinib, generating extensive engagement across the network.

• Dr. Benjamin Besse (@BenjaminBesseMD) sparked critical discussion around treatment sequencing strategies, questioning whether to use "easy osi" then escalate versus upfront combination therapy.

• Dr. Eric Singhi (@lungoncdoc) provided detailed analysis of the MARIPOSA trial with an extensive tweetorial including the intracranial efficacy data, showing improved icPFS and duration of response with the combination.

• Patient advocate Jill Feldman (@jillfeldman4) offered important perspective on toxicity management and shared decision-making.

Key Opinion Leader social insights regarding MARIPOSA across Key Medical Congress Presentations.

MARIPOSA Sentiment Analysis

MARIPOSA Social Network Visualization

The visualization reveals several key insights:

• Dense clustering of interactions around OS data presentation
• Rapid dissemination of key findings through retweets/mentions
• Active engagement between clinicians and patient advocates
• Geographic diversity of participating specialists
• Focus on practical implementation considerations

This network analysis demonstrates how AI tools can map the flow of clinical trial information through the oncology community, identifying key discussion drivers and themes that shape clinical practice.

Interact with the Social Network Visualization👉